Navigation Links
Oxygen Biotherapeutics, Inc. Announces Closing of Private Placement Financing Agreement
Date:7/16/2009

COSTA MESA, Calif., July 16 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bullletin Board: OXBO) today announced that the company has closed on the first $5 million financing tranche with the Vatea Fund, Segregated Portfolio under a June 8, 2009 securities purchase agreement.

For additional details on the agreement, please see the Form 8-K filed with the SEC on June 8, 2009, which is available on the SEC website at www.sec.gov and through the investor relations page of the company website at www.oxybiomed.com.

About Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and Defense Medicine(TM). The company has under development a perfluorocarbon (PFC) therapeutic oxygen carrier and liquid ventilation product (Oxycyte(R)) and has out-licensed an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs as well as medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle cell crisis pain, trauma, wound care, decompression sickness, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, diabetes and cosmetic applications. More information is available at www.oxybiomed.com.


'/>"/>
SOURCE Oxygen Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Brain Monitor Eliminates Need for Routine Oxygen With Propofol - Friedberg's Triad Unveiled
2. Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
3. Oxygen Biotherapeutics, Inc. CEO Posts New Blog Entry
4. Webcast Alert: Oxygen Biotherapeutics, Inc. Investor Meeting in Zurich, Switzerland
5. Oxygen Biotherapeutics, Inc. Adds Oxycyte TBI Clinical Trial Sites in Israel
6. Oxygen Biotherapeutics, Inc. Expands Board of Directors
7. Bion Announces Approval of New Australian Patent for Low Oxygen Organic Waste Bioconversion for Livestock Waste Environmental Treatment
8. Sangart, Inc. Completes Enrollment in Second Phase III Study of Hemospan, a Novel Oxygen Transport Agent
9. Finesse Introduces TruFluor(TM) DO, a Single-Use Optical Dissolved Oxygen Sensor and Transmitter
10. Senexis and O2H (Oxygen Healthcare) Announce Medicinal Chemistry Collaboration
11. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... , Nov. 24, 2014   Veracyte, Inc. ... H. Anderson , president and chief executive officer, will present ... th Annual Healthcare Conference on Tuesday, December 2, 2014 ... . The live audio webcast and subsequent replay ... . Please connect to the website at least 15 minutes ...
(Date:11/24/2014)... 2014 Deep Research Report on ... professional and in-depth research report on the Adipic ... its definition, classification, application, and industry chain structure ... the international market analysis, including China’s domestic market ... Europe, Asia, China, Japan etc. regions) industry analysis ...
(Date:11/24/2014)... -- Senior Vice President, General Manager for ... business acumen Elsevier , a world-leading ... services, congratulates Diane Bartoli , Senior Vice President ... Clinical Solutions, for being recognized in the 13 th ... of Profiles in Diversity Journal ® . ...
(Date:11/22/2014)... 2014 During his lifetime Richard L. ... to surround himself with great people and take risks ... friends often marveled at his extraordinarily courageous attitude when ... and -- even with his death impending—that’s how he ... that would ultimately take his life. , Carrying on ...
Breaking Biology Technology:Veracyte to Present at the Piper Jaffray 26th Annual Healthcare Conference 2Adipic Dihydrazide Industry 2019 Research Forecasts on Worldwide, China Regions Now Available at ReportsnReports.com 2Adipic Dihydrazide Industry 2019 Research Forecasts on Worldwide, China Regions Now Available at ReportsnReports.com 3Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 2Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 3Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 3
... to high quality, practice management and reimbursement content ... available through web-based delivery platform, DALLAS-FORT ... develops products and services to help accelerate,advancements in the ... in web-based delivery of healthcare,information, have joined forces to ...
... Aton Pharma, Inc., a,global specialty pharmaceutical ... an expanded, comprehensive distribution program that ... resources, for the,dry eye medication Lacrisert(R) ... unique preservative-free, once-daily*, sustained,release prescription insert ...
... the active elements in the next generation of electronic ... nanotubes within device architectures. Most of the approaches for ... applicable to discrete devices and are not readily scalable ... nanotube-based chips. Now, this seemingly intractable problem has been ...
Cached Biology Technology:Oncology Metrics and E-Expert Reimbursement Partners Announce Joint Marketing and Product Development Agreement 2Oncology Metrics and E-Expert Reimbursement Partners Announce Joint Marketing and Product Development Agreement 3Aton Pharma Introduces Expanded Distribution of Lacrisert(R) (hydroxypropyl cellulose ophthalmic insert) at Hawaiian Eye 2Aton Pharma Introduces Expanded Distribution of Lacrisert(R) (hydroxypropyl cellulose ophthalmic insert) at Hawaiian Eye 3Nanotubes go with the flow 2
(Date:11/6/2014)... metastasis, yet progress in preventing and treating migratory ... particularly challenging to design drugs that work against ... biology at Harvard Medical School. , "Unfortunately, ... metastasized." , Gujral and colleagues have now identified ... understand how metastasis begins. Their findings may also ...
(Date:11/6/2014)... 6, 2014 - Insilico Medicine, Inc, a Baltimore-based ... age related diseases announced a research collaboration with ... Champions Oncology, Inc (OTC: CSBR). , "There are ... medicine, but Champions Oncology,s TumorGraft technology is unique ... chemotherapy regimen experimentally generating vast amounts of valuable ...
(Date:11/5/2014)... career to understanding the Earth,s climate and communicating ... deputy director and regional climatologist for the Western ... Redmond has more than three decades of experience ... data to the general public. , At its ... December 15-19, 2014 the American Geophysical Union (AGU) ...
Breaking Biology News(10 mins):Migration negation 2Migration negation 3Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2Nevada climatologist to be honored at AGU Fall Meeting for lifetime of public outreach 2
... Duchenne muscular dystrophy (DMD) face a future of rapidly weakening ... failure before their 30th birthday. While researchers are hopeful that ... have targeted the heart of the problem as much as ... grant he received from the National Institutes of Health will ...
... of toxicity in the four hemophilia B patients enrolled to ... development at St. Jude Children,s Research Hospital and UCL (University ... This trial was designed primarily as a safety test, with ... little detectable Factor IX. The Factor IX protein helps the ...
... LLC, the image analysis and pattern recognition technology ... was awarded best performance for forensic signature verification ... Handwriting Recognition (ICFHR2010) in Kolkata, India, held November ... participants representing a total of 10 offline signature ...
Cached Biology News:New NIH grant helps MU scientist get to the heart of muscular dystrophy 2Early safety results promising for Phase I/II trial of gene therapy treatment of hemophilia B 2Parascript SignatureXpert Wins Forensic Signature Verification Competition 2
Mouse Anti-human CD11b/Mac-1alpha, clone LM2/1, Monoclonal Antibody...
Mouse monoclonal [1-N-14] to Adenovirus Type 7 hexon C11 Immunogen: Purified Adenovirus type 7 Specificity: This antibody is specific for Adenovirus type 7 hexon C11....
... The epitope is specific for Kir2.1 ... other known protein.,SPECIES REACTIVITIES: The ... bovine, porcine and guinea pig. It ... mouse (17/19 residues) and chick (15/19 ...
Request Info...
Biology Products: